Supplemental figures

Figure S1. Time-course of RSK and FAK phosphorylation following PLX4720 treatment. WM1366 cells were treated with 1 μM PLX4720 for times ranging from 15 min to 20 h. Lysates were analyzed by Western blotting with antibodies for (p)RSK-S380, RSK2 (Cell Signaling Technology, Danvers, MA); (p)FAK-S910 and total FAK.

Figure S2. PLX4720 treatment does not alter G1 to S phase cell cycle regulators. (a) Sbcl2, WM1361 and WM1366 cells (mutant N-RAS), and WM983 and 1205Lu (B-RAF^{V600E}) cell lysates from Figures 1a and 1b (treated with 1 μM PLX4720 or 10 μM U0126 for 16 h) were analyzed by Western blotting for cyclin D1 (BD Transduction, San Jose, CA) and ERK1/2. (b) Lysates from Figure 2b (Sbcl2 and WM1366 cells treated with 1 μM PLX4720 for 15 min to 20 h) were analyzed by Western blotting with antibodies for p27 (Kip1) (BD Transduction, San Jose, CA), p21 (Cip1) (Cell Signaling Technology), actin (Sigma Aldrich, St. Louis, MO) and cyclin D1.





